Clinical Trial Update: Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on Aganirsen for ischemic central retinal vein occlusion patients at risk of neovascular glaucoma, involving Phase 2 and Phase 3 evaluatio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ischemic Central Retinal Vein Occlusion
• Neovascular Glaucoma

Drugs mentioned

• Aganirsen (Aganirsen)

Snippet

Sponsor: Gene Signal SAS | Conditions: Ischaemic Central Retinal Vein Occlusion, Neovascular Glaucoma | Phase 2, Phase 3 | Status: UNKNOWN